The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
- Industry Trends
- Draft Report on Proposed EU Critical Medicines Act Prioritizes Manufacturing Competitiveness, but Expands Stockpiling Provisions
- GSK Announces $30B Five-Year Investment in US R&D and Manufacturing, but Maintains UK Presence
- Industry Analysis
- Contract service agreements
- Contract manufacturing - opportunities and threats
- Quarterly mergers, acquisitions, and financing - Q3 2025
- Value Chain
- Compounding
- API chemical
- API biologics - protein and peptide
- API biologics - cell, gene, vaccine, and virus
- Commercial dose manufacturing and packaging
- Clinical dose manufacturing and packaging
- Analytical services
- About the Analyst
- About the Authors
- Contact the Publisher
Table 1: Contract service agreements
Table 2: Contract manufacturing: opportunities and threats - potentially positive
Table 3: Mergers, acquisitions, and financing - Q3 2025
List of Figures
Figure 1: Contract service agreements by deal geography, by volume
Figure 2: Deals by deal geography, by volume
Figure 3: The contract manufacturing value chain
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ACS Dobfar SpA
- Aenova Holding GmbH
- AGC Biologics Inc
- Akadeum Life Sciences Inc
- Andelyn Biosciences Inc
- Amplo Biotechnology Inc
- Ardena Holding NV
- AstraZeneca Plc
- Astellas Pharma Inc
- BioFactura Inc
- Biogen Inc
- Biomay AG
- Boehringer Ingelheim Fremont Inc
- Boehringer Ingelheim Pharma GmbH & Co KG
- Bora Pharmaceuticals Co Ltd
- Capitol Biologics
- Catalent CTS LLC
- Catalent Inc
- Charles River Laboratories International Inc
- Chiesi Farmaceutici SpA
- Cirsium Biosciences Inc
- Corden Pharma International GmbH
- Cytovance Biologics Inc
- DGr Pharma BV
- Eli Lilly and Co
- Esteve Pharmaceuticals SA
- Esteve Quimica SA
- Exothera
- Famar Health Care Services
- Flamma SpA
- Forge Biologics Inc
- FUJIFILM Biotechnologies USA Inc
- GSK (GlaxoSmithKline)
- Genentech Inc
- Johnson & Johnson
- Kyowa Kirin Co Ltd
- Lotte Biologics Co Ltd
- Made Scientific Inc
- Maxona Pharmaceuticals Inc
- Merck & Co Inc
- Neurosense Therapeutics Ltd
- Nelson Laboratories LLC
- NewAmsterdam Pharma
- NextPharma Technologies Holding Ltd
- Northwest Biotherapeutics Inc
- Organon & Co
- Oxford BioMedica Plc
- Pace Analytical Services LLC
- Patheon NV
- Pfizer Ltd
- Piramal Pharma Solutions Inc
- Quratis Inc
- Recipharm
- Recipharm AB
- ROVI Pharma Industrial Services SA
- Rottendorf Pharma GmbH
- Samsung Biologics Co Ltd
- Sanofi
- Siegfried Holding AG
- Simtra US LLC
- Snapdragon Chemistry Inc
- Tonix Pharmaceuticals Inc
- Vetter Pharma-Fertigung GmbH & Co KG
- Wisconsin Pharmacal Co LLC
- WuXi Biologics Ireland Ltd
- WuXi STA (Shanghai) Co Ltd
- WuXi XDC Cayman Inc
